Sign In
Buy PRNB
$100.05
+0 (+0%)
At Close: May 27, 2022
Sanofi to Acquire Principia Biopharma for $3.7 billion; Analysts Optimistic on Outlook
10:33am, Monday, 17'th Aug 2020
Sanofi SA, a French multinational pharmaceutical company headquartered in Paris, said it would acquire a U.S.-based biopharmaceutical company Principia Biopharma for approximately $3.7 billion, sendin
Sanofi to Acquire U.S. Biotech Principia Biopharma for $100 a Share
09:45am, Monday, 17'th Aug 2020
Sanofi will acquire Principia Biopharma in an all-cash deal with an equity value of about $3.68 billion.
Dow Futures, Barrick Gold, Sanofi, Principia Biopharma - 5 Things You Must Know Monday
09:27am, Monday, 17'th Aug 2020
Wall Street is coming off its third straight week of gains; Sanofi to acquire U.S. biotech Principia Biopharma; Warren Buffett builds a position in Barrick Gold.
Sanofi Inks Deal To Buy Principia Pharma For $3.68 Billion
09:05am, Monday, 17'th Aug 2020
French drugmaker Sanofi announced Monday that it entered into an agreement to acquire US company Principia Biopharma in an all-stock deal valued at $3.68 billion to help the companies build a portfoli
Sanofi To Purchase Immune System-Focused Drugmaker Principia Biopharma For $3.7B
08:14am, Monday, 17'th Aug 2020
Sanofi SA (NASDAQ: SNY) will acquire Principia Biopharma Inc (NASDAQ: PRNB) for $3.68 billion in cash, the two companies announced Monday.What Happened Under the agreement, the French drugmaker will p
Merger Arbitrage Mondays - Qiagen Shareholders Want More
08:04am, Monday, 17'th Aug 2020
Merger activity increased significantly last week with eight new deals announced. The acquisition of Principia Biopharma by Sanofi.
Sanofi to Buy U.S. Autoimmune Drugmaker in $3.4 Billion Deal
06:03am, Monday, 17'th Aug 2020
(Bloomberg) -- Sanofi plans to acquire U.S. biotech company Principia Biopharma Inc in a $3.4 billion deal as the French drugmaker pivots toward innovative therapies to spur growth under new Chief Exe
French group Sanofi to buy U.S. firm Principia Biopharma for $3.7 billion
05:56am, Monday, 17'th Aug 2020
French healthcare company Sanofi SA has agreed to buy U.S. company Principia Biopharma Inc for around $3.7 billion, the companies said on Monday, strengthening Sanofi's presence in research and develo
Sanofi to acquire Principia Biopharma
05:00am, Monday, 17'th Aug 2020
Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under whic
Sanofi to acquire Principia Biopharma
01:00am, Monday, 17'th Aug 2020
Sanofi to acquire Principia Biopharma
A Peek Into The Markets: US Stock Futures Rise Following Prior Week's Gains
12:00am, Monday, 17'th Aug 2020
Pre-open movers
U.S. stock futures traded higher in early pre-market trade, after recording gains in the previous week. The Empire State manufacturing index for August is...
Principia Biopharma Reports Second Quarter 2020 Financial Results
08:05pm, Thursday, 06'th Aug 2020
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated dis
Analysts Estimate Principia Biopharma Inc. (PRNB) to Report a Decline in Earnings: What to Look Out for
04:30pm, Thursday, 06'th Aug 2020
Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Did Hedge Funds Drop The Ball On Principia Biopharma Inc. (PRNB) ?
05:10pm, Monday, 03'rd Aug 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
Biotech Bonanza - Second Half Outlook
08:24am, Tuesday, 28'th Jul 2020
Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest cre
